Gossamer Bio has announced a private placement agreement valued at up to $250m, including $150m of committed capital intended to support the development and potential US Food and Drug Administration (FDA) approval of seralutinib.
Seralutinib is intended for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension ****** ociated with interstitial lung disease (PH-ILD).
The private investment comprises an initial closing, a subsequent closing contingent upon FDA acceptance of a new drug application (NDA) for seralutinib in PAH and warrants exercisable upon FDA approval.
The company plans to submit the NDA by September 2026. The proceeds will help advance seralutinib's clinical development and potential commercialisation, with net funds expected to sustain operations until 2028.
Gossamer recently regained global rights to seralutinib.
#Potential #approval
Seralutinib is intended for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension ****** ociated with interstitial lung disease (PH-ILD).
The private investment comprises an initial closing, a subsequent closing contingent upon FDA acceptance of a new drug application (NDA) for seralutinib in PAH and warrants exercisable upon FDA approval.
The company plans to submit the NDA by September 2026. The proceeds will help advance seralutinib's clinical development and potential commercialisation, with net funds expected to sustain operations until 2028.
Gossamer recently regained global rights to seralutinib.
#Potential #approval
2 months ago
